Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
116 hedge funds and large institutions have $252M invested in Enzo Biochem, Inc. in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 32 increasing their positions, 49 reducing their positions, and 12 closing their positions.
190% more call options, than puts
Call options by funds: $700K | Put options by funds: $241K
0% more funds holding
Funds holding: 116 → 116 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
19% less capital invested
Capital invested by funds: $313M → $252M (-$60.7M)
35% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EGA
Evermore Global Advisors
Summit,
New Jersey
|
+$8.38M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.87M |
| 3 |
Renaissance Technologies
New York
|
+$1.89M |
| 4 |
Millennium Management
New York
|
+$1.57M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$2.24M |
| 2 |
MCM
McKinley Capital Management
Anchorage,
Alaska
|
-$1.97M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$974K |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$947K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$810K |
ENZ Hedge Fund Activity: Q4 2017 in Review
116 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2017, worth a combined $252M — down 19% from $313M a quarter earlier.
Fund positioning in ENZ was balanced in Q4 2017: 12 funds opened new positions, 12 closed out, 32 added to existing stakes and 49 trimmed.
The largest buyer was Evermore Global Advisors, adding an estimated $8.38M. The largest seller was EAM Investors, exiting entirely with an estimated $2.24M sold.
- 116 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $252M of Enzo Biochem, Inc. stock for Q4 2017, down 19% quarter-over-quarter.
- 12 funds opened new Enzo Biochem, Inc. positions in Q4 2017 and 12 closed out, a net change of 0 holders.
- The largest Enzo Biochem, Inc. buyer in Q4 2017 was Evermore Global Advisors, an estimated $8.38M added.
- The largest Enzo Biochem, Inc. seller in Q4 2017 was EAM Investors, an estimated $2.24M sold.
Based on aggregated 13F filings for Q4 2017.